Note: Descriptions are shown in the official language in which they were submitted.
WO 01/54704 CA 02401590 2002-08-28 ~ PCT/USO1/01186
11294/ 1
1 PHYSIOLOGICALLY BALANCED. IONIZED, ACIDIC SOLUTION AND
2 METHODOLOGY FOR USE IN WOUND HEALING
3 BACKGROUND OF THE INVENTION
4 1. Field of the Invention
This invention relates to a physiologically balanced, ionized, acidic solution
that
6 is useful in wound healing and other applications in which antimicrobial
properties are
7 desirable. Preferably, the ionized solution is prepared by electrolysis,
i.e. it is an
8 electrolyzed solution. In addition, the invention relates to a methodology
of using the
9 solution of the invention, including a specialized bandage which may be used
in
combination with the solution or with other solutions or topically applied
materials.
11 2. Brief Description of the Background Art
12 Various electrolyzed acidic salt solutions, their properties, and their
uses have
13 been described in the art. Several examples are provided below.
14 U.S. Patent No. 5,622,848, issued April 22, 1997, to Morrow, discloses a
microbicidal solution for in vivo and in vitro treatment of microbial
infections. The
16 solution comprises an electrolyzed saline containing regulated amounts of
ozone and
17 active chlorine species, wherein the ozone content is between about 5 and
100 mg/L, and
18 the active chlorine species content is between about S and 300 ppm. The
active chlorine
19 species comprises free chlorine, hypochlorous acid, and the hypochlorite
ion, as
measured by a chlorine selective electrode. The solution is prepared by
subjecting a 1%
21 or less saline solution to electrolysis under conditions sufficient to
produce the desired
22 active ingredients. The solution is preferably utilized at an isotonic
saline concentration,
23 and may be adjusted with hypertonic saline. The solution may be used for in
vitro
24 treatment of infected whole blood, blood cells, or plasma to reduce
contamination, and
may be used in the treatment of fluids infected with HIV, hepatitis, and other
viral,
26 bacterial, and fungal agents. The solution may also be administered to warm-
blooded
27 animals, including humans, by intravenous injection or other modes, for
similar
WO 01/54704 CA 02401590 2002-08-28 ° PCT/USO1/01186
11294/ 1
1 purposes.
2 PCT publication I~ o. W09934652, published July 8, 1999, of Marais,
discloses
3 the use of an electrochemically activated sodium hypochlorite-free
irrigating medium to
4 reduce the proliferation of bacteria and other microorganisms during tooth
root canal.
Anion- and canon-containing solutions are obtained by electrolysis of a 10%
aqueous
6 NaCI solution. The anion-containing solution is used at a pH of about 2 - 7
and an
7 oxidation reduction potential (ORP) of about +1170 mV; the cation-containing
solution
8 is used at a pH of about 7 - 13 and an ORP of about -980 mV.
9 X. W. Li et al. (Chinese J. Epidem., 17(2), pp. 95 - 98, 1996) reported a
preliminary study of the microbicidal effect of electrolyzed oxidizing water.
11 Electrolyzed oxidizing water was shown to completely kill Staphylococcus
aureus and
12 Escherichia coli within 1 S seconds, while 10 minutes were required to
completely kill all
13 spores of Bacillus subtilus var. niger. Thirty seconds were needed to
destroy the
14 antigenicity of HBsAg. The oxidation reduction potential and pH values of
electrolyzed
oxidizing water were not significantly changed when stored for three weeks at
room
16 temperature under air-tight, light-free conditions.
17 A. Iwasawa et al. (J. Jap. Assoc. Infec. Diseases, 70(9), pp. 915 - 922,
1996)
18 evaluated the bactericidal effect of acidic electrolyzed water on S.
aureus, S. epidermidis,
19 and Pseudomonas aeruginosa. At pH 5.0 to approximately 6.0, three bacterial
strains
were killed soon after being exposed to the acidic water containing 50 mg/L
chloride,
21 and the chloride concentration reportedly did not change after standing
open for 6 hours.
22 At pH 2.67 to approximately 2.80, the bactericidal effects were observed at
a chloride
23 concentration of
24 5 mg/L, and 80% of the chloride reportedly remained after standing open for
6 hours.
H. Tanaka et al. (J. Hosp. Infect., 34( 1 ), pp. 43 - 49, 1996) reported on
the
26 antimicrobial activity of superoxidized water. Superoxidized water is
described as "a
27 strong acidic and colorless solution with a high oxidation-reduction
potential. The
28 solution is prepared by mixing a small amount of salt with tap water in an
electrolyser".
2
WO U1/547~4 CA 02401590 2002-08-28 " PCT/USO1/01186
11294/ 1
I The antimicrobial activity of superoxidized water was tested against
methicillin-sensitive
2 S. aureus, Serratia marcescens, E. coli, P. aeruginosa, and Burkholderia
cepacia. The
3 number of bacteria was reduced below the detection limit following
incubation in
4 superoxidized water for 10 seconds. The bactericidal activity of
superoxidized water was
S similar to that of 80% ethanol, but superior to that of 0.1 % chlorhexidine
and 0.02%
6 povidone iodine.
7 Y. moue et al. (Artificial Organs, 21 ( 1 ), pp. 28 - 3 I , 1997) reported
on the use of
8 electrolyzed strong acid aqueous solution lavage in the treatment of
peritonitis and
9 intraperitoneal abscess. Peritoneal and abscess lavages were performed using
an
electrolyzed strong acid aqueous solution to treat seven patients with
peritonitis and
11 intraperitoneal abscesses. The period of irrigation in the seven patients
ranged from 9 to
12 12 days, with conversion to microorganism negative state observed within 3
to 7 days.
13 The authors describe the solution as being "acidic water that contains
active oxygen and
14 active chlorine and possesses a redox potential"
1 S S. Sekiya et al. (Artificial Organs. 21 ( 1 ), pp. 32 - 38, 1997) reported
on the use of
16 electrolyzed strong acid solutions in the treatment of infectious skin
defects and ulcers
17 using. The clinically applied therapy of electrolyzed strong acid aqueous
solutions were
18 found to be effective in the treatment of infectious ulcers. Sekiya et al.
describe the
19 strong aqueous solution (ESAAS) as being "generated by electrolyzing water
and a small
quantity of salt with a canon transfer filter."
21 H. Hayashi et al. (Artificial Organs, 21 ( 1 ), pp. 39 - 42, 1997) reported
on the use
22 of electrolyzed strong acid aqueous solutions (ESAAS) in the treatment of
mediastinitis
23 following cardiovascular surgery. Hayashi et al. described ESAAS as being
"produced
24 by electrolyzing sodium chloride solution. (. . .) ESAAS is produced by
electrolyzing the
sodium chloride solution using an ion-exchange membrane that separates the
positive
26 and negative electrodes. A small amount of sodium chloride is added to the
water to
27 facilitate electrolysis and increase the concentration of dissolved
chloride." The
28 mediastinal wound was left open and irrigated with ESAAS one to three times
daily
3
WO 01/54704 CA 02401590 2002-08-28 '' PCT/USO1/01186
11294/1
1 until the infection was eradicated. Satisfactory growth of granulation
tissue was
2 observed in all patients treated, with no evidence of adverse effects
attributable to
3 ESAAS.
4 N. Tanaka et al. (Artificial Organs, 23(4), pp. 303 - 309, April 1999)
reported on
the use of electrolyzed strong acid aqueous solutions to clean and disinfect
hemodialysis
6 equipment. The solutions were found to directly inactivate bacterial
endotoxins, and
7 proved to be more economical than the conventional disinfecting method. The
8 "electrolyzed strong acid aqueous solutions are disclosed to be "strongly
acidic water
9 which is made by electrolyzing tap water containing 50 - 1000 ppm salt (NaCI
> 99
pure) in a cell partitioned by a polyester diaphragm. It has an acidity of 2.3
- 2.7 pH,
11 more than 1,000 mV in oxidation-reduction potential and 10 - 50 ppm in
available
12 chlorine."
13 J. B. Selkon et al. (J. Hosp. Infec., 41 ( 1 ), pp. 59 - 70, January 1999)
evaluated the
14 antimicrobial activity of a new superoxidized water, STERILOXOO (Sterilox
Medical
Limited, 85 E Milton Park, Abingdon, Oxon OX 14 4RY, UK) for the disinfection
of
16 endoscopes. This superoxidized water is described as being "generated at
the point of
17 use by passing a saline solution over coated titanium electrodes at 9 amps.
The product
18 generated has a pH of 5.0 - 6.5 and an oxidation reduction potential of >
950 mV." The
19 antimicrobial activity of STERILOXOO was tested against Mycobacterium
tuberczzlosis,
M. avizrm-intracellulare, M. chelonae, E. coli (including type 0157),
Enterococcus
21 faecalis, P. aeruginosa, B. subtilus var. niger spores, methicillin-
resistant S. aureus,
22 Candida albicans, poliovirus type 2, and human immunodeficiency virus HIV-
1. Under
23 clean conditions, freshly generated STERILOXOO was found to be highly
active against
24 all these microorganisms, giving a 5 logo (99.999%) or greater reduction in
2 minutes or
less.
26 K. S. Venkitanarayanan et al. (Appl. c~ Env. Microbiol., 65(9), pp. 4276 -
4279,
27 September 1999) evaluated the efficacy of electrolyzed oxidizing water for
inactivating E.
28 coli Ol 57:H7, Salmonella enteritidis, and Listeria monocytogenes. A five-
strain mixture
4
CA 02401590 2002-08-28
WO 01/54704 PCT/USO1/01186
11294/ 1
1 of E. coli 0157:H7, S. enteritidis, or L. monocytogenes was inoculated in
electrolyzed
2 oxidizing water at various temperatures, for various time periods. The
electrolyzed
3 oxidizing water is produced from a saline base solution containing
approximately 12
4 by weight NaCI. At 4°C and 23 °C, an exposure time of S
minutes, the population of all
S three pathogens in the treatment samples was reported to be reduced by
approximately 7
6 log CFU/mL, with compete inactivation by 10 minutes of exposure. A reduction
of
7 greater than 7 log CFU/mL in the levels of the three pathogens was reported
to occur in
8 the treatment samples incubated for 1 minute at 45 °C or for 2
minutes at 35 °C.
9 SUMMARY OF THE INVENTION
This invention relates to physiologically balanced, ionized, acidic solutions
and to
11 a methodology for their use, including a specialized bandage which may be
used in
12 combination with the solutions, or with other topically applied materials.
Preferably the
13 ionized solutions are prepared by electrolysis, i.e. they are electrolyzed
solutions.
14 The composition of the invention is prepared using a mixture of inorganic
salts in
physiologically balanced proportions. A mixture of inorganic salts and,
optionally
16 minerals, (such as metallic elements, for example and not by way of
limitation) is used in
17 order to mimic the electrolyte concentration and mixture of body fluid in
an isotonic state.
18 The solution typically comprises halide salts of sodium, potassium,
calcium, arid other
19 cations. Typically the halide is fluoride, chloride, bromide, or iodide,
and most typically
chloride. The concentrations of these salts in combination with particular
minerals are
21 such that they give the electrolyzed composition its unique properties.
22 In accordance with the present invention, we have created a composition
23 comprising a physiologically balanced, electrolyzed acidic solution, where
the starting
24 solution prior to electrolysis comprises a total concentration of halide-
comprising salts
ranging from about 0.4 g/L to about 16 g/L; more preferably ranging from about
4 g/L to
26 about 12 g/L; and, most preferably, ranging from about 5.2 g/L to about 6.2
g/L. The
27 solution may optionally contain other salts or minerals. The electrolyzed
solution has a
5
CA 02401590 2002-08-28
WO 01/54704 PCT/USO1/01186
11294/ 1
1 pH within the range of about 2 to about 6, an oxidation reduction potential
within the range
2 of about +600 mV to about +1200 riV, and a titratable halide (X) content
within the range of
3 about 10 ppm to about 100 ppm, where X is F -, C1 - , Br ' , or I - .
4 The starting solution used to prepare the physiologically balanced,
electrolyzed, acidic
composition of the invention preferably comprises a plurality of halide -
comprising salts
6 selected from the group consisting of sodium halide, potassium halide,
magnesium halide,
7 calcium halide, zinc halide.
8 The starting solution of halide-comprising salts, and optionally other salts
and
9 minerals, is converted to acidic water through electrolysis. The
electrolyzed, halide
comprising solution has a typical oxidation reduction potential (ORP) of about
+600 to
11 +1200 mV. The pH of the electrolyzed, chlorine-comprising solution is
typically lowered to
12 about 6 or less, giving the solution bactericidal, fungicidal, and
sporicidal properties. The
13 halide-comprising acidic solution is physiologically balanced by the
inclusion of elements
14 such as sodium, potassium, magnesium, zinc, lithium, and beryllium in the
solution.
Typically these elements are supplied in the form of halide-comprising salts
which are
16 ionized during electrolysis. Preferably, these physiologically-balancing
halide-comprising
17 salts are selected from the group consisting of sodium halide, potassium
halide, magnesium
18 halide, zinc halide, lithium halide, beryllium halide, and combinations
thereof. Most
19 preferably the salts are selected from sodium chloride, potassium chloride,
magnesium
chloride, zinc chloride, and combinations thereof.
21 A particularly preferred starting solution for preparation of the
electrolyzed solution
22 includes sodium chloride present at a concentration ranging from about 0.3
g/L to about 14
23 g/L, potassium chloride present at a concentration ranging from about 0.02
g/L to about 0.8
24 g/L, and magnesium chloride present at a concentration ranging from about
0.01 g/L to about
0.5 g/L, prior to electrolysis.
26 The electrolyzed acidic solutions contain, among other components, hydroxyl
free
6
WO 01/54704 CA 02401590 2002-08-28 '' PCT/USO1/01186
11294/ 1
1 radicals, oxygen, ozone, hypochlorous acid, hydrochloric acid, and hydrogen
peroxide.
2 These are the same oxidizing agents involved in physiological systems
associated with
3 wound healing and tissue repair and regeneration. For example, hypochlorous
acid is the
4 chief bactericidal agent produced by neutrophils at sites of inflammation,
injury, and wounds.
An adequate supply of oxygen is particularly important in collagen synthesis.
In vitro studies
6 have shown that the rate at which fibroblasts synthesize collagen is
proportional to the
7 extracellular oxygen concentration. In addition, increased crosslinking of
collagen fibers,
8 which is responsible for the increase in tensile strength of collagen, is
observed in healing
9 skin wounds with increases in the concentration of available oxygen. In vivo
studies have
also shown that granulation tissues in healing leg ulcers exposed to excess
oxygen are
11 characterized by abundant fibroblast proliferation.
12 The solutions of the invention are physiologically balanced and, when
applied to
13 infected wounds, enhance the process of healing substantially.
Antimicrobial properties of
14 acidic water solutions have been tested against many organisms, including
Escherichia coli,
Listeria monocytogenes, Staphylococcus aureus, methicillin-resistant S. aureus
(MRSA),
16 Pseudomonas aeruginosa, Lactobacillus, yeast, vancomycin-resistant
enterococcus, molds,
17 and spores. Vancomycin-resistant bacteria, MRSA, and others are easily
destroyed by the
18 solutions of the present invention. The solutions of the invention are
osmotically balanced,
19 environmentally friendly, and have minimal cytotoxicity. For example, no
cytotoxicity was
observed in rabbits' eyes nor in in vitro cytotoxicity studies carried out to
date.
21 The composition of the invention is nontoxic and has antibacterial
properties. The
22 composition is useful in any application in which antimicrobial properties
are desirable.
23 Such applications include, without limitation, treatment of wounds, burns,
and canker
24 sores; irrigation; cleaning of tissue sites (e.g., pre- and post-
operative); ophthalmic
applications (e.g., in contact lens cleaning solutions or for irrigation of
the eye during
26 ophthalmic surgery); for dermatological applications, psoriasis; and
numerous
27 applications which are readily apparent to one skilled in the art. Unlike
many other
28 solutions used in similar applications, the composition of the invention
has minimal to no
7
W~ 01/54704 CA 02401590 2002-08-28 ~'' ~w pCT/USO1/01186
11294/ 1
1 side effects. For example, in Draize testing in Rabbit eyes, when compared
to other
2 antiseptic solutions, the physiologically balanced, electrolyzed, acidic
solution of the
3 present invention behaves in a manner similar to saline solution. The
composition of the
4 invention can be incorporated into a bandage or wound dressing, as described
subsequently herein. The physiologically balanced, electrolyzed, acidic
solution may be
6 used in combination with a specially designed bandage in a wound treatment
protocol as
7 described subsequently herein. The specialized bandage includes an opening
or
8 "window" through which topical treatment materials such as the solution of
the present
9 invention may be applied.
Also disclosed herein is an article of manufacture comprising the composition
of
1 I the invention packaged in a container. Surfaces of the container which are
in contact with
12 the composition of the invention are made of material which is not reactive
with an
13 oxidizing agent.
14 BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a cross-sectional schematic of an electrolyzing unit I having two
16 compartments, identified in Figure 1 as elements 2 and 3. Compartments 2
and 3 are
17 separated by a semipermeable membrane 4. A positive electrode 5 is located
in
18 compartment 2, where a strong acidic solution 6 is generated. A negative
electrode 7 is
19 located in compartment 3, where an alkaline solution 8 is generated.
Electrodes 5 and 7
are connected to a power source 9 which generates a current across
semipermeable
21 membrane 4. A lid 10 keeps electrolyzing unit 1 free from ambient air 11.
22 Figure 2A is a schematic top view of an air-permeable bandage 200,
including
23 outer portion 201 having a primary adhesive border 202; an inner portion
210 including a
24 lifting flap 205 having a secondary adhesive border 207, a lifting tab 204,
which assists in
the lifting of flap 205, a hinge 206, and a dew/humidity indicator 208 (or
other
26 sensor/indicator as will be described subsequently herein)..
8
WO 01/54704 CA 02401590 2002-08-28 ,. ,... pCT/LTSO1/01186
11294/ 1
1 Figure 2B is a schematic side view of air-permeable bandage 200, showing
lifting
2 flap 205 and lifting tab 204 in a partially lifted position, to provide a
window opening 203
3 through bandage 200. A portion of secondary adhesive border 207 has been
lifted above
4 the upper surface 209 of bandage 200.
Figure 2C is a schematic cross-sectional view of air-permeable bandage 200,
with
6 lifting flap 205 and lifting tab 204 in a lowered position, secured to upper
surface 209 of
7 bandage 200 by secondary adhesive border 207.
8 Figure 3 is a schematic cross-sectional view 300 of an air-permeable bandage
200
9 of the kind shown in Figures 2A - 2C, applied over a subcutaneous wound 303.
The
subcutaneous tissue 304 is packed with gauze 306 which has been soaked in the
11 physiologically balanced, electrolyzed, acidic solution 308 of the present
invention. The
12 bandage 200 is adhered to the skin surface 302 by a primary adhesive border
202.
13 Bandage lifting flap 205 can be lifted via tab 204 to expose gauze 306 for
the application
14 of additional solution 308 when a dew/humidity indicator (not shown) or
other
sensing/indication device (not shown) indicates a low level of humidity of the
gauze 306.
16 DETAILED DESCRIPTION OF THE INVENTION
17 Described herein are a physiologically balanced, electrolyzed, acidic
solution;
18 methods and apparatus used in the production of the solution; methods for
use of the solution,
19 including the description of a specialized bandage for administering the
solution or other
topically applied treatment materials. Also disclosed are recommended
packaging for the
21 solution.
22 I. THE COMPOSITION OF THE INVENTION
23 The present invention is a physiologically balanced, electrolyzed acidic
solution,
24 which is generated from a starting solution comprising a total
concentration of halide-
comprising salts ranging from about 0.4 g/L to about 16 g/L; more preferably
ranging from
9
CA 02401590 2002-08-28
WO 01/54704 PCT/USO1/01186
11294/ 1
1 about 4 g/L to about 12 g/L; a~ ~d most preferably ranging from about 5 g/L
to about 6 g/L.
2 Optionally, minerals may be added, depending on the end use application.
3 A typical starting solution, prior to electrolysis, by way of example and
not by way
4 of limitation, may comprise a plurality of chloride-comprising salts
selected from the group
consisting of sodium chloride, potassium chloride, magnesium chloride, calcium
chloride,
6 zinc chloride, and combinations thereof. Additional chloride-comprising
salts such as lithium
7 chloride and beryllium chloride may be added, depending on the application.
8 For purposes of providing particular physiologically balancing
characteristics,
9 combinations of various halogen-comprising salts may be used. For example,
and not by way
of limitation, sodium chloride may be used in combination with potassium
fluoride, which
11 may be used in combination with lithium iodide.
12 A mixture of salts, providing varying cations to the starting solution,
enables mimicing
13 of the electrolyte concentration and mixture of body fluid in an isotonic
state. The various
14 salts are provided in particular concentration ranges which give the
composition its unique
1 S properties.
16 Preferred concentration ranges for the various chlorine-comprising salts to
be used in
17 the starting solution used to prepare an electrolyzed solution are
presented in Table 1, below.
18 Table 1. Compositions of Preferred Chloride-Containing Salts In Preferred
Embodiment
19 Starting Solutions For Preparation Of An Electrolyzed Acidic Solution
Preferred More Preferred Most Preferred
(
NaCI (g/L) 0.33 - 14.6 3.6 - 11.0 4.7 - 5.5
21 KCI (g/L) 0.02-0.9 0.2-0.7 0.3-0.33
22 MgCI, (g/L) 0.01 - 0.5 0.1 - 0.4 0.16 - 0.19
23
24 The properties of the physiologically balanced, electrolyzed acidic
solutions produced
from the Starting Solutions described in Table 1 are presented in Table 2,
below.
i: .
WO 01/54704 CA 02401590 2002-08-28 " '" PCT/USOl/01186
11294/ 1
1 Table 2. Properties of Preferred Ph solo i~cally-Balanced Electrolyzed
Acidic Solutions
2 Generated From The Starting Solutions Listed in Table 1
Preferred More PreferredMost Preferred
3 ORP (mV) +600 to +1200+800 to +1160+1000 to +1150
4 pH 2.0-6.0 2.2 - 4.5 2.4 -3.5
Hypochlorite 0.1 - 1000 1 - 500 10 - 100
6 Conc.(ppm)
7 03 conc. (ppm) 0.001 - 5 0.01 - 3 0.1 - 1.5
8 Soluble O, Conc. 5 - 30 10 - 25 20 - 25
(ppm)
9 As shown in Table 3, below, the physiologically-balanced, electrolyzed
acidic
solution of the invention and tap water typically have very different
properties.
11 Table 3. Comparison Of Properties of A Preferred Pysiolo ig cally-Balanced
Electrolyzed
12 Acidic Solution and Typical Tap Water
Electrolyzed Acidic SalineTap Water
Solution
(T ical Pro erties)
13 ORP (mV) +1146 +740
14 pH (at 18C) 2.5 7.3
Conductivity 1980 245
(s/cm)
16 Hypochlorites 10 0.4
(ppm)
17 Ca++ (ppm) 21 26
18 Mg++ (ppm) 36 6.7
19 Na+ (ppm) 1,600 16
K+ (ppm) 190 2.4
21 C1- (ppm) * 27
22 Soluble O~ (ppm)25
23
*
Not
measured.
CA 02401590 2002-08-28
WO 01/54704 PCT/USO1/01186
11294/ 1
1 II. APPARATUS AND METHOD FOR MAKING THE PHYSIOLOGICALLY
2 BALANCED, ELECTROLYZED, ACIDIC WOUND HEALING SOLUTIONS
3
4 The physiologically-balanced, acidic solution of the invention is prepared
using
electrolysis. Electrolysis of water is the process by which the hydrogen ions
are reduced,
6 providing hydrogen gas, and the hydroxide ions are oxidized, providing
oxygen gas.
7 The wound healing solution described herein was prepared using a SUNTRON~
8 M WB-2 model electrolyzing unit of the kind manufactured by Koshin Co. Ltd.,
Kyoto, Japan.
9 Equivalent wound healing solutions can be prepared using a SUPER OXSEED
LABO~
electrolyzing unit of the kind manufactured by ARV Co., Japan.
11 With reference to Figure 1, which shows a general schematic of an
electrolyzing unit
12 in which a physiologically balanced , electrolyzed, acidic wound healing
solution is prepared,
13 and with reference to the SUNTRON~ MWB-2 model electrolyzer, the
electrolyzing unit 1
14 has a first compartment 2 and a second compartment 3, each of which have a
capacity of
about 3 liters. Compartments 2 and 3 are separated by a semi-permeable
membrane 4. In the
16 first compartment 2, a positive electrode 5 is located. In the first
compartment 2 a strong
17 acidic solution 6 is generated. In the second compartment 3, a negative
electrode 7 is located.
18 In the compartment 3, an alkaline solution 8 is generated. Electrodes 5 and
7 are connected
19 to a power source 9 which generates a 0.9 A, 100V current. A lid 10 keeps
the electrolysis
unit free from contamination by ambient air 11.
21 A salt mixture was prepared by adding 14.2 g of KCl (J.T. Baker), 8.05 g of
22 MgCl,,6H,0 (J.T. Baker) and 235.5 g NaCI (non-iodated, Morton). This salt
mixture was
23 added to tap water at a concentration of 5.38 g per Liter of water to
prepare a starting solution.
24 2.5 L of solution was placed in first Compartment 2 and 2.5 L of solution
was placed in
second Compartment 3. The power source 9, shown in Figure l, was turned on and
power
26 was applied for 15 minutes. The electrolysis was carried out at room
temperature (about 25
27 ° to 30 °C), with no external heat added and no heat removed.
28 Salt solutions allow currents to pass between the electrodes, accelerating
the process
29 of electrolysis. The amount of salt necessary to affect the electrolysis
process is minimal.
12
WO 01/54704 CA 02401590 2002-08-28 ~- °° pCT/USOi/01186
11294/1
1 During the electrolysis process, a halide salt, such as sodium chloride is
in ionized form, as
2 shown below.
3 HZO
4 NaCI -~ Na+ + CI-
S During electrolysis of saline, the sodium ions are attracted to the
negatively charged
6 electrodes, and will counterbalance the hydroxide ions on the alkaline side;
the chloride ions
7 travel to the positive electrode. The chloride ions then undergo an
oxidative process which
8 results in the generation of small quantities of chlorine gas that are
immediately consumed to
9 form hypochlorous acid, as illustrated below.
-2 e-
11 2 C1' -~ C12
12 H~O + Cl, -> HC10 + C1- + H+
13 Chloride ions in saline are in the form of either HC10, CIO-, or C1-; the
balance among
14 these ions is greatly affected by the pH of the solution. Only HC10 and CIO-
ions are effective
sterilizing agents, with HC10 being ten times more effective than C10-. In
acidic pH, most
16 of the C10- ions are in the form of HC10. Under electric current, low
levels of 03 are formed
17 according to the following reactions.
18 HZO -~ H+ + OH-
19 -4e
4 OH- -1 2 H~O + O,
21 -2e-
22 HZO + O, -~ 03 + 2 H+
23 The combination of hypochlorous acid and ozone synergistically enhances the
anti-
24 microbial properties of the solution of this invention.
Other halide salts undergoing electrolysis participate in similar ionization
processes,
26 which are well known and documented in the art.
27 The properties of the physiologically-balanced, electrolyzed acidic
solution prepared
28 in the manner described above are presented in Table 3.
29 A typical physiologically-balanced, electrolyzed acidic solution of the
invention has
13
CA 02401590 2002-08-28
WO 01/54704 '"" PCT/USO1/01186
11294/ 1
1 a concentration of sodium cG tions ranging from about 0.005 g/L to about 7
g/L, a
2 concentration of potassium ca:ions ranging from about 0.005 g/L to about 0.6
g/L, a
3 concentration of magnesium caticns ranging from about 0.005 g/L to about 0.1
g/L. It is the
4 presence of this combination of cations, and optionally other cations
previously described,
which provide the physiological balancing of the electrolyzed acidic solution.
6 A typical physiologically-balanced, electrolyzed acidic solution produced
using the
7 starting materials described of the invention has a low pH (about 2 to about
6), an HC10
8 concentration of about 0.1 ppm to about 1000 ppm, an 03 concentration of
about 0.001 ppm
9 to about 5 ppm, and an O, concentration of about 5 ppm to about 30 ppm. This
combination
of chemicals gives the electrolyzed acidic saline solution of the invention
its superior
11 antiseptic ability.
12 Standard electrolysis equipment, including the particular apparatus named
herein, can
13 be used in the manufacture of the electrolyzed salt solutions of the
invention, as previously
14 mentioned.
Following manufacture, the solutions of the invention must be stored for use.
16 Packaging is very important in extending the useful shelf life of the
solutions. In particular,
17 the surfaces of the container which make contact with the solution should
be made of a
18 material which tends not to react with oxidizing agents.
19 We evaluated a number of different container materials, and surprisingly
discovered
that while a glass contacting surface preserves the long term strength
(potency) ofthe solution,
21 plastic surfaces are, in general, not as helpful. By way of example and not
by way of
22 limitation, chemically resistant, coated soda lime amber glass 1 L or 500
mL bottles
23 (manufactured by Lawson Mardon Wheaton, Millville, NJ 08332), meeting the
requirements
24 for Type III as established by the United States Pharmacopoeia, Volume
XXIII (1995), and
supplements thereto, under "Chapter <661>, Chemical Resistance-Glass
Containers" make
26 excellent storage containers for the physiologically-balanced,
electrolyzed, acidic solutions
27 of the present invention. These bottles also meet the requirements for
light protection
28 established by the USP under Chapter <661>, "Light Transmission", which may
be helpful
14
WO 01/54704 CA 02401590 2002-08-28 ~ °' PCT/LTS01/01186
11294/1
1 in some instances. The bottle cap is fabricated from phenolic, and has a
liner facing made out
2 of TEFLON~ (PTFE) which is less reactive than phenolic, and which helps seal
the cap,
3 preventing the passage of ambient air into the bottle. This bottle is
available from AllPak
4 Corp., Bridgeville, PA .
A white (clear) glass bottle produced by the same manufacturer (AllPak Corp.),
but
6 absent the amber coloring also appears to function well.
7 We conducted a study of the shelf life of the solution described above with
reference
8 to Tables 2 and 3, in terms of pH and oxidation-reduction potential (ORP) in
bottles made out
9 of various materials. Freshly prepared solution was stored over a period of
3 months in 4
types of bottle: The amber glass; the white (clear) glass; High Density
PolyEthylene (HDPE);
11 and TEFLONO.
12 At given times, known aliquots were withdrawn to measure the pH and ORP.
13 Results are reported in the following graphs.
W~ 01/54704 CA 02401590 2002-08-28 ~~~~~ '° pCT/USO1/01186
11294/1
1 GRAPH # 1: Effect of Storage on the pH of the Solution
3.4
3.2
3
i
IZ 2.8
Q.
i
2.4
' I
2.2 j
2
0 10 20 30 40 50 60 70 80 90I'~
Days
2 GRAPH #2: Effect of Storage on the ORP of the Solution
_ ~~00. .__._____.__- _.______. _______.__ .___
_._- - __ - _____-_ _.
X000 ' ! T
60~ a~5
y
et C~ ss
P~'~. ~~a_ __ __ __. _ .__ ____
00 -~- ~Q~G
~l, ~~~\o~ __._- _.__ __._
--
0 ,~0 ~,0 30 ~0.~% ~0 60 ~0 ~0 90.
16
ii ,.
W~ 01/54704 CA 02401590 2002-08-28 '~~~ "' PCT/US01/01186
11294/ 1
1 When the physiologically-balanced, electrolyzed, acidic solution of the
invention is
2 stored in a glass bottle, the composition has been shown to be stable for at
least 60 days.
3 This compares with electrolyzed solutions of sodium chloride described in
the prior art,
4 where storage in plastic bottles is recommended, and reported stability is
96 hours or less.
As previously described, electrolysis ionizes the various salts contained in
the
6 starting solutions used to generate the physiologically-balanced acidic
solutions of the
7 invention to produce oxidizing agents which are known to be involved in
physiological
8 systems associated with wound healing and tissue repair and regeneration.
Antimicrobial
9 properties of acidic saline solutions prepared solely from sodium chloride
salt have been
tested against many organisms, as described below.
11 Antimicrobial Activity
12 Antimicrobial efficacy of electrolyzed acidic water was tested against
13 microorganisms including Pseudomonas aeruginosa, Escherichia coli,
Staphylococcus
14 aureus, Listeria monocytogenes 10403s wild type, catalase-deficient mutant
L.
monocytogenes LM1370, Aspergillus niger (spores), Penecillium oblatum
(spores),
16 Lactobacillus, and E. coli O157:H7. Up to 5 logs of reduction in the
activity of the
17 microorganisms was achieved after 10 to 60 seconds of exposure to
electrolyzed acidic
18 water.
19 Effects of electrolyzed acidic water on the prevention of hospital-acquired
infections (Y. Nakamura and A. Iwasawa, presented at the Japanese Functional
Water
21 Symposium, December 1997). Antimicrobial activity of electrolyzed acidic
water was
22 tested against 238 strains of 69 species, including bacteria, fungi, and
viruses. Three to
23 five logs of reduction in microbial activity were achieved after 5 to 15
seconds of
24 exposure to the electrolyzed acidic water in most cases. Microorganisms
used for testing
included S. aureus (MRSA), Streptococcus pyogenes, S. pneumoniae, P.
aeruginosa, E.
26 coli, E. coli 0157:H7, Bacillus cereus, Mycobacterium tuberculosis, Candida
albicans,
17
~r~~ "
WU 01/54704 CA 02401590 2002-08-28 '' 'h'~ PCT/USOl/01186
11294/1
1 Cryptococcus neoformans, Micnosporum car,!is, Herpes simplex virus,
Influenza virus
2 A/PR/8, and Coxsackie virus A 16, among others.
3 Eye and Skin Irritation
4 Primary eye irritation and 5-day skin cumulative irritation studies of
electrolyzed
acidic water were carried out using male New Zealand white rabbits (M.
Takeyoshi et al.,
6 presented at the Japanese Functional Water Symposium, 1994). In the primary
eye
7 irritation study, 0.1 mL of electrolyzed acidic water was instilled into
each eye of six
8 rabbits. In three of the rabbits, the treated eyes were irrigated for 30
seconds after
9 instillation to evaluate the irritation effects. Since no signs of
irritation were observed in
any of the treated eyes, the electrolyzed acidic water was classified as non-
irritating to the
11 rabbit eye according to the AFNOR scale ( 1992).
12 In cumulative skin irritation studies, two intact and two abraded skin
sites were
13 prepared on the skin on the back of each of six animals. Then, 0.5 mL of
electrolyzed
14 acidic water was applied to one intact skin site and one abraded skin site
on each animal
for 4 hours a day for a period of 5 days; 0.5 mL of distilled water was
applied to the
16 second intact skin site and the second abraded skin site on each animal for
the same time
17 period, as a control. No cumulative skin irritation effects were noted at
the application
18 sites of the electrolyzed acidic water compared to the distilled water.
19 We have studied the antimicrobial properties of the solutions of the
present
invention as well as the behavior of these solutions with respect to eye and
skin irritation
21 and find exciting results, which are described below.
22
23 III. METHODS FOR USING THE COMPOSITION OF THE INVENTION
24 Application of the physiologically-balanced, electrolyzed, acidic solution
of the
present invention, which is rich in oxygen and contains some ozone (the key
elements in
26 enhancing wound healing), helps wound healing progress remarkably.
Antimicrobial
27 properties of acidic electrolyzed salt solutions are such that they enhance
the healing
28 process of any wound contaminated with microorganisms. The compositions of
the
18
CA 02401590 2002-08-28
WO 01/54704 PCT/USO1/01186
11294/ 1
1 invention function specifically to maintain the necessary antibacterial
environment for
2 wounds to heal faster, without the usual complications associated with
superficial
3 infections. In addition, the solutions provide topical bacterial control and
humidification
4 of chronic wounds. The use of acidic electrolyzed salt solutions has been
instrumental in
healing a number of patients with deep wounds which were not responding to
usual
6 medications and locally applied treatments.
7 The physiologically balanced, electrolyzed acidic salt solutions of the
invention
8 have been shown to be effective at healing wounds that are provided with a
good blood
9 supply. Our preliminary studies have indicated that a much faster rate of
healing is
achieved than with prior art compositions, with patients reporting less pain
during their
11 recovery period.
12 Three recent case studies involving the treatment of human subjects with a
13 preferred composition of the invention are presented below. In these case
studies, the
14 electrolyzed acidic salt solution was essentially the same as that
described for the
Electrolyzed Acidic Solution in Table III. This composition provides
osmolarity similar
16 to that of blood plasma. The wounds were kept continuously moist with the
composition
17 of the invention, and were covered with Vaseline gauze to prevent
evaporation of the
18 solution.
19 Case Study # 1
The patient was a 70 year-old female, with a long history of severe venous
edema,
21 lymphaedema, and obesity. Her vascular supply was normal. She developed a
cutaneous
22 ulcer 2 years ago in the lower right leg. A second ulcer subsequently
developed in the
23 lateral right leg. The ulcers had previously been treated using multiple
methods,
24 including debridement, antibiotics, topical solutions including BETADINEOO
(Purdue
Frederick, Norwalk, Connecticut); SILVADINEOO (BASF Corporation, Mt. Olive,
New
26 Jersey); ELASE ~ (Fujisawa Co., Deerfield, Illinois); and FURACINO (Roberts
27 Pharmaceutical Corp., Meridian Center, Illinois). By way of explanation,
BETADINE~
28 is an antiseptic cleanser, used externally on wounds; an iodine-containing
preparation
19
CA 02401590 2002-08-28
WO 01/54704 PCT/USO1/01186
11294/ 1
1 used as a broad spectrum antimicrobial. SILVADINE~ is a soft white cream
containing
2 1% silver sulfadiazine antimicrobial agent which is applied to wounds after
cleaning and
3 debriding. ELASE~ is an enzymatic powder or cream used as a debridement
agent in
4 wounds where circulation is poor, to destroy dead tissue and leave healthy
tissue intact.
S FURACIN~ is a nitrofurazone broad-spectrum antibacterial cream used against
6 pathogens commonly causing surface infections. Use of these agents in the
wound
7 healing had not produced the desired results.
8 A biopsy revealed benign ulceration and granulation tissue. The possibility
of
9 Pyodermo Gangrenosum was considered. The initial measurements of these
severely
necrotic ulcers were 130 x 180 mm and 98 x 125 mm. Treatment included bedrest,
11 debridement, antibiotics, and topical application of the composition of the
invention, for
12 hydration and topical bacterial control. Within 10 days, the ulcers were
almost
13 completely covered with crisp red granulation tissue and the pain was gone.
Within 14
14 days, a split thickness skin graft closed the wound; the patient was able
to leave the
1 S hospital 8 days later. Within two months following the start of treatment,
the ulcers had
16 completely healed, and the patient remained pain-free.
17 Case Studv #2
18 The patient was a 50 year-old male, with a history of thrombophlebitis,
pulmonary
19 emboli, and obesity. The patient had experienced infected hematomatous
ulceration in
both groins and bilateral venous ulcers in both legs for several months. He
had an
21 antithrombin III deficiency and had been coumadinized. By way of
explanation,
22 Antithrombin III is a protein consisting of normal plasma and extracellular
sites that
23 inactivates thrombin in a time-dependent irreversible reaction and serves
as a cofactor of
24 heparin into its anticoagulant activities. Antithrombin III also inhibits
certain coagulation
factors-occurs in certain disease process i.e. liver disease or may be
genetic.
26 Coumadinized refers to the use of crystalline warfarin tabs or Heparin LV.
Anticoagulant
27 to treat patients who have thrombosis to prevent further thrombus.
COUMADINE~ is
1r..: ,
WU 01/54704 CA 02401590 2002-08-28 ° _" pCT/USO1/01186
11294/ 1
1 manufactured by DuPont~ Pharmaceutical, Wilmington, Delaware.
2 Because of the recent hemorrhages in his groin, he developed large deep
3 ulcerations on the right (measuring 140 x 90 mm) and more superficial
ulcerations on the
4 left (50 x 50 mm and 60 x 60 mm). After the first debridement of infected
necrotic fat,
the culture revealed the presence of vancomycin-resistant Enterococcus.
Treatment
6 consisting of topical application of the composition of the invention was
started.
7 Infectious disease consultation recommended no further antibiotic treatment.
Topical
8 dressings consisting of sponges soaked with the composition of the invention
were
9 packed into the wound and the patient was subjected to bedrest. The distal
venous ulcers
healed fairly rapidly and required only two more debridements. The left groin
ulcer
11 undermined and required opening further while the packing was soaked with
the
12 composition of the invention. The patient then began healing, with good
granulation
13 tissue forming and epidermal coverage to 90% in the right groin ulcer. The
left groin
14 ulcer required debridement for undermining, but began healing without
antibiotic
treatment.
16 Case Study #3
17 The patient was a 57 year-old male, who had experienced recurrent ulcers of
both
18 feet and ankles over the past four years. Local wound care had initially
been started by
19 coagulating veins and using topical wound therapy. His UNNAOO boots caused
an
increase in his ulcerations, which then became more severe. By way of
explanation, an
21 UNNA~ boot is an elastic adhesive bandage applied over zinc oxide cream as
a
22 protective treatment. An UNNAOO boot is a boot-like dressing of the lower
extremity
23 made of layers of gauze and UNNA~ 's paste; 100% soft cotton gauze
impregnated with
24 non-hardening zinc oxide paste. The manufacturer of UNNAOO's paste is
Glenwood, Inc.
of Tenalty, New Jersey. He had been using a JOBST~ pump for edema control.
This
26 pump is designed for intermittent home use and is connected to an
inflatable pneumatic
27 appliance which is typically preset to alternate 90 seconds of inflation
with 30 seconds of
21
W~ 01/$4704 CA 02401590 2002-08-28
PCT/USO1/01186
11294/ 1
1 deflation. The manufacturer of JOBSTOO pumps is Nutech, of San Antonio,
Texas.
2 At the time we examined the patient, his wound measurements were 33 x 65 x 2
3 mm, 17 x 25 x 2 mm, and 5 x 9 x .'.. mm. Physical evaluation verified
excellent pulsatile
4 inflow to the leg; the wounds were therefore diagnosed as venous ulcers
because of the
significant edema present. The patient began compression therapy and
debridement,
6 culturing the leg at the same time; the bacteria present were found to be
coagulase-
7 negative, methicillin-resistant Staphylococcus and Enterococcus sensitive to
vancomycin.
8 He also had Haemophilus and diphtheroids cultured with polymicrobial
infection. The
9 patient had persistent nonhealing infections for several months, and the
infections had
become resistant to the classic antibiotic treatments. The infections were
only sensitive to
11 CIPROFLOXACIN u0 and BACTRIM DSO. CIPROFLOXACIN~ is a broad spectrum
12 antibiotic, manufactured by Miles Pharmaceutical, West Haven, Connecticut,
which is
13 active on Gram+ and Gram- bacteria, and is typically used to treat skin,
bone and joint
14 infections. BACTRIM DSO is manufactured by Roche of Nutley, New Jersey.
BACTRIM DS~ is a sulfonamide antibiotic, which is typically used to treat
urinary tract
16 infections, ans is also used to treat E. coli, Proteus species, Shegellosis
and Pneumocystic
17 pneumonia infections. The patient was started on CIPROFLOXACINOO , which
was then
18 discontinued, and then BACTRIM DS~ was started. He had topical
debridements.
19 Since no significant improvement was shown after the treatment described
above,
topical application of the composition of the invention was begun for control
of the
21 bacteria and hydration. The infections were rapidly controlled after the
start of treatment
22 with the composition of the invention, and the wounds began healing fairly
rapidly. He
23 has now shown healing of the two ulcers, with the final measurements down
to 7 x 41
24 mm and 7 x 11 mm on the right medial and lateral ankle, respectively.
Oral Care
26 The physiologically-balanced, electrolyzed, acidic solution of the
invention may
27 be used to treat canker sores (mouth ulcers) or cold sores by rinsing the
affected area. The
22
WO 01/54704 CA 02401590 2002-08-28 w ° PCT/USO1/01186
11294/1
1 solution can be used by soaking the cold sore 3-4 times a day, each time
with 2-3
2 applications, and putting the solution in contact with the sore for 20-30
seconds. The
3 solution may also be used as a mouth rinse for dental and mouth hygiene and
to control
4 infection. In this instance, the solution may be used as a gargling solution
to fight throat
infection. The solution may be applied with the help of a cotton swab for more
specific
6 areas. The solution can be used once or several times a day according to
patient's needs
7 and condition.
8 Ophthalmic Care
9 The physiologically-balanced, electrolyzed, acidic solution of the invention
may
be used in place of a saline solution to remove a foreign body from, to rinse,
or to irrigate
11 the eyes. It can also be applied topically before or after surgery to
disinfect an eye and
12 surrounding tissues. Our studies on rabbits eyes showed that this solution
is as safe as
13 saline solution when applied to rabbits' eyes and has no toxicity to the
eyes when
14 compared to ophthalmic grade BETADINE ~ (5%) typically used pre-surgery.
The
1 S solution can be used once or several times a day according to a patient's
needs and
16 condition. The solution can be applied by dropping it directly into the
eyes as necessary.
17 It can also be applied by soaking a gauze and applying the saturated gauze
to the eyes for
18 1 or several minutes. It can also be used to clean the eyes by gently
wiping the eyes with a
19 saturated gauze. The solution can also be poured into a small eye washer,
then the washer
is inverted over the eye washer and the eyelid opened and closed several
times.
21
22 The reader will see that the solution of the invention has applications in
the
23 treatment of many different types of wounds, including, without limitation,
diabetic
24 ulcers, gangrene, venous ulcers, decubitus ulcers, pressure ulcers, wounds
due to bites,
acute trauma wounds, surgical wounds and burns. The composition of the
invention is
26 also useful as an irrigation solution, for example, during dental,
periodontal, and
27 ophthalmic procedures. The composition of the invention can also be used
for pre- and
23
WU 01/54704 CA 02401590 2002-08-28 " " PCT/LJS01/01186
11294/1
1 post-operative cleaning of tissue sites, and as a gargling solution for
treatment of canker
2 sores. In addition, because of its active oxidants, the solution of the
invention may be a
3 strong growth factor stimulator in the wound healing process. As such, the
solution may
4 find uses in many other applications in which disinfection and growth factor
stimulation
are desirable.
6 Method of Wound Care
7 Patients suffering from long-lasting non-healing wounds should be treated
with the
8 physiologically-balanced, electrolyzed, acidic solution of the present
invention on a daily
9 basis, typically about 3 times a day. The solution of the invention should
used be in place
of a saline solution, to control infection and to help the wound healing
mechanisms. The
11 solution of the invention may be used as follows: a gauze material or gauze
pad is
12 presoaked with enough solution to saturate it and is then squeezed to
remove excess
13 solution. This removes species present in the gauze which would react with
and reduce
14 the effectivity of the solution of the invention. The gauze is wet after
this procedure, but
not soaked. Additional solution is then applied to completely wet the gauze,
which is
16 then immediately applied to the wound. In the alternative, the gauze may be
applied to
17 the wound and then additional solution applied. Typically the wound site is
packed with
18 the solution-soaked gauze, and optionally, a vasoline gauze can be applied
on top of the
19 packed wound to keep it moist and free of contaminating germs. The wound
site is then
wrapped with wound dressings as is standard in the art. The solution may also
be used to
21 clean a wound by pouring it directly on the wound site to remove any
necrotic tissue by a
22 mechanical procedure, and also as a cleanser or irrigant.
23 The patient may also make use of a "wound care kit" provided by California
24 Pacific Lab which permits the patient to periodically pour the solution of
the present
invention onto the wound site without having to remove the dressing. This kit
provides
26 ease-of use, portability and dramatically reduce exposure of the wound. The
wound care
27 kit includes a package containing the solution of the invention and
bandaging material.
24
WO 01/54704 CA 02401590 2002-08-28 'v~° °- PCT/USO1/01186
11294/1
1 Preferably the kit contains a package containing the solution of the
invention and a
2 specialized bandage for use in combination with the solution. The
specialized bandage
3 keeps the skin surrounding the wound dry while the wound is treated.
Further, the
4 bandage may be applied in a physician's office or at a hospital, with the
patient
continuing care at home; may be applied and used at home under the
instructions of a
6 physician; or for minor injuries, the wound care kit may be used as an "over
the counter"
7 treatment by the patient alone.
8 IV. DESCRIPTION OF THE WOUND CARE KIT
9 The wound care kit includes bandaging material and a package of the solution
of
the invention. Preferably the packaging material provides the kind of non-
reactive (with
1 I the solution) surface previously described herein. In addition, the
bandaging material
12 preferably includes a specially designed wound "bandage" made out of an
oxygen-
13 permeable bandage material to prevent the wounded tissue from drying.
Figures 2A - 2C
14 and Figure 3 describe the bandage and illustrate the use of the bandage on
a wound
surface, respectively. The bandage is described in more detail subsequently.
The kit may
16 also include gauze or a similar material for packing of the wound, to be
used in
17 combination with the solution and a bandage.
18 V. DESCRIPTION OF THE SPECIALIZED BANDAGE
19 The specialized bandage of the present invention comprises an opening,
which
may also be described as a "window" through which the solution of the
invention or other
21 topical material may be applied periodically as needed depending on the
indication.
22 Preferably, the bandage includes a dew/moisture sensor, an electrically-
conductive sensor
23 which measures ion content, or other bandage property sensor which provides
an
24 indication of the status of the bandage related to treatment of the wound.
For example,
and not by way of limitation, a dew/moisture indicator which provides a
colored
26 indication when the bandage solution content has become low, or a signal-
producing
z: .
WO U1/54704 CA 02401590 2002-08-28 w w pCT/US01/01186
11294/1
1 device such as a sound indicator or an electrical signal output indicator
when the ion
2 content of the treatment solution has become low so that the bandage is no
longer
3 sufficiently effective.
4 One embodiment of the bandage invention is shown in Figures 2A - 2C, The
bandage 200 includes an outer portion 201 having a primary adhesive border
202; an
6 inner portion 210 including a lifting flap 205 having a secondary adhesive
border 207, a
7 lifting tab 204, which assists in the lifting of flap 205, and a hinge 206.
Optionally the
8 bandage has a dew/humidity indicator 208, or an electrically-conductive
sensor, where the
9 sensor may be attached to a signal generator, which occupies a position
within inner
portion 210 of bandage 200. Figure 2B is a schematic side view of air-
permeable
11 bandage 200, showing lifting flap 205 and lifting tab 204 in a partially
lifted position, to
12 provide a window opening 203 through bandage 200. A portion of secondary
adhesive
13 border 207 has been lifted above the upper surface 209 of bandage 200.
Figure 2C is a
14 schematic cross-sectional view of air-permeable bandage 200, with lifting
flap 205 and
lifting tab 204 in a lowered position, secured to upper surface 209 of bandage
200 by
16 secondary adhesive border 207. One skilled in the art can envision a number
of similar
17 designs which will accomplish the function and utility of the bandage in a
similar manner,
18 and such designs are considered to be included in the present invention.
19 Figure 3 is a schematic cross-sectional view 300 of an air-permeable
bandage 200
of the kind shown in Figures 2A - 2C, applied over a subcutaneous wound 303.
The
21 subcutaneous tissue 304 is packed with a packing material 306 such as
gauze, which has
22 been treated to reduce or eliminate reactivity with oxidants and then
soaked in the
23 physiologically balanced, electrolyzed, acidic solution 308 of the present
invention. The
24 bandage 200 is adhered to the skin surface 302 by a primary adhesive border
202.
Bandage lifting flap 205 can be lifted via tab 204 to expose packing material
306 for the
26 application of additional solution 308 when desired. A dew/humidity
indicator (not
27 shown), or electrically-conductive indicator (not shown) may be used to
indicate the
28 appropriate time for addition of solution 308.
26
WO 01/54704 CA 02401590 2002-08-28 '~ -- PCT/USO1/01186
11294/ 1
1 The bandage provides ease-of use to the patient by allowing him to pour the
2 solution onto his wound or onto wound packing without having to remove the
entire
3 dressing. A more complicated version of the bandage, such as one having an
electrically-
4 conductive sensor which may be connected to monitoring equipment is
particularly
helpful in a hospital setting.
6 Accordingly, the above described preferred embodiments are not intended to
limit
7 the scope of the present invention, as one skilled in the art can, in view
of the present
8 disclosure, expand such embodiments to correspond with the subject matter of
the
9 invention claimed below.
27
